Itraconazole Analogs and Use Thereof
    3.
    发明申请
    Itraconazole Analogs and Use Thereof 有权
    伊曲康唑类似物及其用途

    公开(公告)号:US20140221393A1

    公开(公告)日:2014-08-07

    申请号:US14343040

    申请日:2012-09-07

    IPC分类号: C07D405/14

    摘要: Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

    摘要翻译: 本文提供伊曲康唑类似物。 本文还提供了抑制Hedgehog途径,血管内皮生长因子受体2(VEGFR2)糖基化,血管生成和伊曲康唑类似物治疗疾病的方法。

    Immunosuppressive agents that inhibit calcineurin function and uses of these agents
    6.
    发明授权
    Immunosuppressive agents that inhibit calcineurin function and uses of these agents 失效
    抑制钙调磷酸酶功能的免疫抑制剂和这些药物的用途

    公开(公告)号:US06686450B1

    公开(公告)日:2004-02-03

    申请号:US09335011

    申请日:1999-06-17

    IPC分类号: A61K3816

    摘要: The present invention provides novel immunosuppressive agents. In particular, the invention provides immunosuppressive agents that bind calcineurin and/or that inhibit interaction between calcineurin and NF-AT. The invention also provides analogs of these agents, nucleic acids encoding the agents and/or their analogs, gene therapy vectors, etc., and methods of making and using them.

    摘要翻译: 本发明提供了新的免疫抑制剂。 特别地,本发明提供了结合钙调神经磷酸酶和/或抑制钙调神经磷酸酶和NF-AT之间相互作用的免疫抑制剂。 本发明还提供了这些试剂的类似物,编码试剂和/或其类似物的核酸,基因治疗载体等,以及制备和使用它们的方法。

    Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
    7.
    发明授权
    Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof 失效
    2型甲硫氨酸氨基肽酶[MetAP2]抑制剂及其用途

    公开(公告)号:US06207704B1

    公开(公告)日:2001-03-27

    申请号:US09093448

    申请日:1998-06-08

    IPC分类号: A61K31336

    摘要: Novel compounds that are anti-angiogenic or immunosuppressive are described. Also described are methods for determining if an animal is at risk for a disease involving abnormal angiogenesis or an immune reaction resulting in pathology comprising evaluating an aspect of MetAP2 metabolism or structure; methods for identifying agents that are anti-angiogenic or immunosuppressive comprising evaluating the effect of the agent on an aspect of MetAP2 metabolism; methods for treating a cell having an abnormality in metabolism or structure of MetAP2; and methods for treating abnormal angiogenesis or an immune reaction which results in pathology in an animal. Pharmaceutical compositions are also provided.

    摘要翻译: 描述了抗血管生成或免疫抑制的新型化合物。 还描述了用于确定动物是否处于涉及异常血管发生的疾病或导致病理学的免疫反应的风险的方法,包括评估MetAP2代谢或结构的一个方面; 用于鉴定抗血管生成或免疫抑制剂的试剂的方法,包括评估试剂在MetAP2代谢方面的作用; 用于治疗MetAP2的代谢异常或结构异常的细胞的方法; 以及用于治疗导致动物病理学的异常血管生成或免疫反应的方法。 还提供药物组合物。